Elan wins shareholder approval to complete Perrigo sale
DUBLIN (Reuters) - Ireland's Elan won approval from shareholders on Monday to complete the sale of the company to U.S. drugmaker Perrigo, clearing the way for the deal to be completed by the end of the year.
Perrigo agreed to buy the Dublin-based group for $8.6 billion in July in a deal that will hand it tax savings from being domiciled in Ireland and royalties from blockbuster multiple sclerosis treatment Tysabri.
The deal ended a bitter takeover battle in which Elan rejected three lower bids from U.S. investment firm Royalty Pharma.
(Reporting by Padraic Halpin; editing by Keiron Henderson)
- Total CEO de Margerie killed in Moscow as jet hits snow plow |
- Pistorius starts five-year term for killing Reeva Steenkamp
- Ebola crisis turns a corner as U.S. issues new treatment protocols
- U.S. Congress examining deal between NSA official, ex-agency chief
- Fashion designer Oscar de la Renta dead at 82 |